MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

MDT

97.73

+2.28%↑

VEEV

296

-1.38%↓

141.89

+2.46%↑

HQY

88.52

-1.34%↓

PHR.US

23.12

+1.54%↑

Начало・Списък с акции・SCYNEXIS Inc

SCYNEXIS Inc

Отворен

0.79 1.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.77

Максимум

0.81

Ключови измерители
By Trading Economics
Приходи	-1.5M -6.9M
Продажби	1.1M 1.4M
Марж на печалбата	-504.765
Служители	28
EBITDA	-4.3M -9.6M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+400% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	11M 45M
Предишно отваряне	-0.49
Предишно затваряне	0.79

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

0.9307 / 0.9907 Подкрепа & съпротива

SCYNEXIS Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.10.2025 г., 23:30 ч. UTC

Горещи акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2.10.2025 г., 21:21 ч. UTC

Печалби

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3.10.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2.10.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2.10.2025 г., 23:00 ч. UTC

Пазарно говорене

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Scales's JV Buyout Lauded by Bull -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Forex and Fixed Income Roundup: Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.10.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.10.2025 г., 20:49 ч. UTC

Придобивния, сливания и поглъщания

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2.10.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2.10.2025 г., 19:20 ч. UTC

Пазарно говорене

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2.10.2025 г., 19:10 ч. UTC

Пазарно говорене

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2.10.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение с други в отрасъла

Ценова промяна

SCYNEXIS Inc Прогноза

Ценова цел

By TipRanks

400% нагоре

12-месечна прогноза

Среден 4 USD 400%

Висок 4 USD

Нисък 4 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за SCYNEXIS Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на SCYNEXIS Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.9307 / 0.9907Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.